Merck Brings Firepower To Daiichi’s EU Lixiana Campaign
This article was originally published in PharmAsia News
Executive Summary
Following the European approval of Lixiana last year, Daiichi Sankyo has tapped Merck & Co to maximize regional sales of the novel anticoagulant in markets where it has limited reach, but will face multiple competitors.